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This paper reviews the results achieved in murine and primate models of autoimmune disease
and transplantation. These studies have attempted to clarify the nature and specificity of the
response induced by reinfusion of phototreated immunoactive lymphocytes.
Results obtained in murine lupus have demonstrated that some of the disease features related
to the abnormal proliferation of inducer T cells can be inhibited both prophylactically and
therapeutically by exposure to photoinactivated autoimmune splenocytes. Radiolabeling studies
performed in normal syngeneic mice have shown that, ifimmunoactive cells are phototreated and
injected, their recirculation pattern is altered, and increased sequestration in the spleen, bone
marrow, and kidney is noted. These studies suggest that reinfused, phototreated, antigen-
activated lymphocytes may localize in sites where they are available for induction of immune
responses. Primate cardiac xenotransplantation models have demonstrated that reinfusion of
phototreated autologous leukocytes, administered with cyclosporine A and steroids, mediates
enhanced specific suppression of both the cellular and humoral host response to foreign tissue.
Taken as a whole, the experimental models suggest that photopheresis may provide a means of
inducing specific suppression of immunoactive T cells. This form oftherapy may have a role as an
immunosuppressive agent in both autoimmune disease and transplantation.
The dramatic clinical response achieved in erythrodermic patients with the leukemic
form of cutaneous T-cell lymphoma (CTCL), through reinfusion of photoinactivated
autologous lymphocytes, suggested that photopheresis therapy induced a host response
that exceeded the results predicted for simple tumor cytolysis [1]. Clearance of skin
lesions as well as reductions in circulating malignant T cells indicated that this
response was specific for the abnormal cell type. In addition, retention of the delayed
type of hypersensitivity and the absence of infectious complications provided evidence
that generalized immune competence was spared and only active T-cell proliferations
were effected. The contention that these results might be explained by induction of an
autoregulatory host response which recognized phototreated effector T-cell popula-
tions and specifically suppressed them may be addressed in animal model systems
where syngeneic populations are available for experimentation. The results achieved in
these models could then be used to predict those conditions where photopheresis might
invoke a beneficial clinical response. Animal models would also provide insights into
the nature of the mechanism(s) induced in the host after reinfusion of autologous
lymphocytes treated with psoralen and ultraviolet A light.
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MURINE MODELS OF SYSTEMIC LUPUS ERYTHEMATOSUS
The MRL/I mouse model of systemic lupus erythematosus was chosen to evaluate
the effects ofreinfusion ofphototreated autoimmune lymphocytes because many ofthe
features ofthis disease are directly related to an unregulated proliferation ofabnormal
benign inducer T cells [2]. Therapies that affect T cells such as neonatal thymectomy
[3], injection of monoclonal antibodies directed against the pan T-cell antigen, Thyl
[4], or the inducer T-cell marker, L3T4 [5], and whole-body or total-lymphoid
irradiation [6] have been successful in affecting the course of the autoimmune process
in the MRL/l mouse model. The genome of the MRL/I mouse contains the lpr
mutation, which in the homozygous state results in early onset ofautoimmune disease
with massive lymphadenopathy, and splenomegaly due to hyperproliferation of
phenotypically abnormal, benign inducer T cells [2]. These T cells mediate polyclonal
B-cell stimulation, resulting in excess antibody production [7]. Some of these
antibodies are autoreactive in nature and recognize single- and double-stranded (ds)
DNA [8]. Successful therapeutic intervention in this model can be monitored by the
effect on survival, lymphoid organomegaly, T-cell hyperproliferation, and anti-DNA
antibody production. In addition, the abnormal T cells rapidly lose the capacity to
respond to the T-cell mitogen, concanavalin A [9]. Retention ofthe normal blastogenic
response to this mitogen would be consistent with down-regulation of the abnormal
T-cell hyperproliferation.
The first protocol pursued in this system involved the prophylactic treatment of
young mice (six weeks old), prior to the onset of autoimmune disease, with cells
obtained from old, actively diseased mice (17 to 21 weeks old). The goal of these
studies was to determine whether it was possible to inhibit some of the features of the
autoimmune disease by exposing the recipient to phototreated autoimmune cells at a
time when a relatively intact immune system was present [10]. Recipient mice received
biweekly intravenous injections of phototreated cells from autoimmune donors.
Littermate controls were untreated and monitored in parallel. Mice were sacrificed at
weekly intervals to evaluate lymphoid organomegaly, lymphocyte phenotype and
function, and serum anti-ds DNA antibody titers.
The results obtained demonstrated that prophylactic reinfusion of phototreated
autoimmune splenocytes resulted in significantly improved survival, inhibition of
splenic and lymph node hyperplasia, depletion of the abnormal Thyl, LYTI T-cell
population, and reduction of the autoantibody titer to DNA. In addition, the
proliferative response to concanavalin A was maintained for a prolonged period in
treated mice (Table 1). Therefore, the T-cell-related features of autoimmune disease
in this model were suppressed by exposure to phototreated autoimmune effector cells.
These results parallel those found in other systems where T-cell-directed therapies
were used to treat MRL/I mice [3-6]. The results suggest that treated mice recognize
the T-cell hyperproliferation as abnormal and can suppress this cell type if it is
inactivated and presented by the immune system at an early stage of the disease
process.
In addition to the phototherapy group, a set of mice received injections of
unmodified autoimmune splenocytes, and another group of mice received biweekly
treatments with photoinactivated splenocytes that had been disrupted by repeated
freezing and thawing. Recipients of unmodified autoimmune splenocytes demon-
strated a partial response to therapy. While their survival was not improved, lymph
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TABLE I
Effects of Prophylactic Infusion of Photoinactivated Autoimmune Splenocytes on Murine Lupus
Phenotype Mitogen-Sp
Survival LNa SP Anti-DNA
Therapy 50% (weeks) Wt (g) Wt (g) THY1 LYTI AB Con A LPS
Photo-Tx
Autoimmune 26 .53 .37 15b 12 1,436 cpm inc dec
Splenocytes
Un-Tx
Autoimmune 20 .63 .37 66 14 ND dec dec
Splenocytes
Un-Tx
Controls 23 1.18 .52 227 87 10,709 cpm dec inc
aAbbreviations are as follows: LN, lymph node; SP, spleen; Wt, weight; AB, antibody; Con A,
concanavalin A: LPS, lipopolysaccharide; Photo-Tx, Photoinactivation treatment; inc, increased response;
dec, decreased response; Un-Tx, untreated; ND, not done.
bAbsolute number ofreactive cells x 106
node hyperplasia was significantly decreased but not to the extent noted in the
recipients of phototreated autoimmune splenocytes. Splenic hyperproliferation was
reduced in unmodified autoimmune cell recipients when older treated mice were
examined (19 to 34 weeks old), while younger treated mice demonstrated only a
marginal decrease in spleen size. Thyl, LYT1 lymphocytes were depleted in the
spleens of these mice, but to a lesser extent than that observed in phototreated
recipients. The proliferative response to concanavalin A was not improved in the mice
treated with unmodified autoimmune splenocytes (Table 1). The group of mice that
received lysed phototreated cells died rapidly from fulminant autoimmune disease.
These two control groups indicate that intact splenocytes are necessary but not
sufficient for induction of a successful host response to the autoimmune process. The
use of psoralen and ultraviolet A light (UVA) to inactivate the infused autoimmune
cells apparently significantly enhances a partial host response to the autoimmune
process and renders the recipient capable of down-regulating the abnormal T-cell
hyperproliferation. While this protocol was designed to induce an autoregulatory
immune response prior to the onset of autoimmune disease, the treatment remained
effective during the period when active disease is normally expressed. A subsequent
protocol was initiated to determine whether mice that already had established disease
could be treated and some features ofthe disease process inhibited or reversed.
In order to ascertain whether active disease can be suppressed, treatment was begun
in a group ofMRL/l mice at nine weeks ofage, a time when active disease commences
[I I]. These mice were treated weekly and monitored in parallel with untreated
controls to assess survival, lymphoid hyperproliferation, anti-DNA antibody titers, and
proliferative response to the mitogens lipopolysaccharide and concanavalin A. Surviv-
al, probably due to an inability to reverse established kidney disease, was not improved
(Table 2). Lymph node hyperplasia was inhibited, while splenic enlargement was not
significantly decreased. The majority of treated mice tested had decreased levels of
anti-ds DNA antibody. Lymph node cells from treated mice retained the capacity to
respond to both lipopolysaccharide and concanavalin A. These results demonstrate
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TABLE 2
Effects of Therapeutic Infusion of Photoinactivated Autoimmune Splenocytes on Murine Lupus
Mitogen-LN
Survival LNa SP Anti-DNA
Therapy 50% (weeks) Wt(g) Wt(g) AB Con A LPS
Photo-Tx
Autoimmune 20 .44 .49 8/13 decb inc inc
Splenocytes
UN-Tx
Controls 20 .98 .57 2/10 dec dec dec
aAbbreviations: Refer to Table 1.
bAnti-DNA antibody titer decreased (- one standard deviation) below the control mean in 8 of 13 treated
mice as determined in an ELISA assay.
that it is possible to inhibit some features ofthe autoimmune process even when active
disease has been initiated. Clearly this protocol is less efficient than prevention of
disease onset, probably due to the presence of a less competent immune system in
actively diseased mice. In spite of the abnormal T-cell proliferation, it was possible to
reduce lymph node hyperplasia and to maintain a residual normal lymphoid popula-
tion, as demonstrated by the capacity of these cells to respond to mitogens. The
inhibition of anti-DNA autoantibody also probably relates to the suppression of the
abnormal T-cell population which promotes unrestrained B-cell antibody synthesis.
Therefore, in both a prophylactic and a therapeutic model of murine lupus; reinfusion
of phototreated effector cells has resulted in down-regulation of the T-cell-mediated
features of autoimmune disease and retention ofa more normal immune status. These
studies also demonstrate that, in order to be effective, the treatment requires reinfusion
of intact lymphocytes treated with psoralen and UVA and a relatively competent
immune system in the recipient.
Little is known about the fate of the reinfused phototreated cells or their sites of
sequestration in the recipient. To determine whether lymphocytes treated with psora-
len and ultraviolet A are retained in the recipient and iftheir recirculation kinetics are
altered, a protocol was established to investigate the localization sites and residence
time of both resting and antigen-primed phototreated lymphocytes in normal murine
recipients.
RADIOLABELING STUDIES OF PHOTOTREATED ANTIGEN-PRIMED
AND RESTING LYMPHOCYTES IN A NORMAL MOUSE MODEL
These studies were designed to determine whether phototreatment alters the
capacity of reinfused lymphocytes to enter and be retained in various organ systems
[12]. Cells treated with psoralen and UVA have been shown to die gradually in vitro,
probably due to cross-linking of DNA molecules [13]. Reinfusion ofdead or damaged
cells should lead to rapid clearance and absence ofsequestration in normal localization
sites. In addition to resting lymphocytes, the radiolabeling distribution of antigen-
primed cells was studied. Cells that are antigen-activated may serve as the primary
target population that induces a host response after reinfusion. Also, the recirculation
kinetics ofantigen-primed cells may differ from the resting lymphocyte pattern.
Normal syngeneic age-matched mice were used as donors and recipients of
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FIG. 1. The distribution of radioisotope in cpm/g is depicted in organs
obtained from mice receiving injections of resting splenocytes treated with
psoralen and UVA (Photo*) or non-treated (None0) on days 1 and 4. The
cpm/g of ".'In were less than 4 in the thymus, blood, heart, and skin and are
not presented. In, indium; SP, spleen; LN, lymph node; BM, bone
marrow; IN, intestine; LNG, lung; KI, kidney; LI, liver; Photo, photo-
treated.
splenocytes for radiolabeling. Resting splenocytes were radiolabeled directly with
"'indium or phototreated prior to labeling. Approximately 20 x 106 cells were
intravenously injected and pairs ofmicesacrificed at 24-hour intervals. A second group
of mice received splenocytes from mice that had been primed on two occasions with
sheep red blood cells. One set ofantigen-primed splenocytes was photoinactivated prior
to radiolabeling, while the remaining cells were radiolabeled directly. These mice were
studied in a comparable fashion to the recipients of non-immune splenocytes.
The results obtained in recipients of non-immune splenocytes demonstrate that
substantial numbers ofradiolabeled cells persist in the recipient irrespective ofwhether
they have been photoinactivated (Fig. 1). Phototreatment of non-immune cells,
however, decreases the accumulation ofthese cells in the spleen, lymph nodes, thymus,
blood, heart, intestine, and lung. Similar levels of non-treated and photoinactivated
cells were found in the bone marrow, skin, kidney, and liver. Therefore, phototreatment
of non-immune cells did not result in rapid clearance from the recipient, and
substantial numbers of cells could be identified at seven days post-infusion in organs
where non-treated cells were localized. Non-immune cells do not appear to alter their
recirculation kinetics in response to phototreatment, and no increase in sequestration
was found compared to the normal pattern.
Antigen-activation resulted in altered localization in some organ systems (Fig. 2).
Non-treated, antigen-activated cells were found at lower levels in the spleen, blood,
liver, and lung when compared to non-immune cells. In bone marrow, thymus, heart,
skin, intestine, and kidney, antigen-primed splenocytes showed a level ofsequestration
comparable to non-immune cells. When antigen-primed cells were phototreated, an
altered pattern from that observed in non-treated, antigen-activated splenocytes was
identified in some organs. Significantly increased numbers of phototreated antigen-
activated lymphocytes were found in the spleen, bone marrow, and kidney. Levels of
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FIG. 2. The distribution of radioisotope in cpm/g is depicted in organs
obtained from mice receiving injections of antigen-primed splenocytes
treated with psoralen and UVA (Ag-Photo El) or antigen-primed only (Ag
1) on days 1 and 3. Thecpm/gof"'In were lessthan 5 in thethymus, blood,
heart, and skin and are not presented. In, indium; SP, spleen; LN,
lymph node; BM, bone marrow; IN, intestine; LNG, lung, KI, kidney; LI,
liver; Ag-Photo, antigen-primed and phototreated; Ag, antigen-primed
only.
were present in the thymus, blood, heart, skin, lung, and liver. Twenty-four hours
post-infusion, significantly fewer phototreated, antigen-primed splenocytes were pres-
ent in the lymph nodes and intestine ofrecipient animals.
These results demonstrate that phototreatment does not alter the recirculation
kinetics of resting lymphocytes and does not result in rapid clearance of these cells
from the recipient. In addition, an altered pattern of sequestration of phototreated
antigen-activated lymphocytes was found with increased localization of these cells in
the spleen and bone marrow. The persistence of phototreated antigen-primed cells in
these organs may play a role in the promotion of a host response to the reinfused
immunoactive lymphocytes. Kidney accumulation of phototreated cells may reflect
the primary site of clearance of dying phototreated cells. The results support the
contention that reinfusion of autologous immunoactive lymphocytes treated with
psoralen and UVA changes the distribution of these cells in the body and may focus
these cells in sites where immunologic recognition can be achieved.
In addition to murine models, where lymphocyte activation in one syngeneic donor is
used to treat another recipient, autologous reinfusion systems were investigated where
the response to a known antigenic stimulus could be monitored. A primate cardiac
xenograft transplantation model was studied, and the vigorous immune response to a
trans-species graft was monitored.
PRIMATE CARDIAC XENOGRAFT MODEL
In humans, allotransplantation of donor organs has been successfully developed
through the use of cyclosporine A, steroids, and other immunosuppressive agents. An
acute shortage of donor organs has made the search for alternative organ sources
imperative. Primates are closely related to man and clearly would offer the best source
for procurement of foreign tissue. While suppression of the response to alloantigen is
primarily cellular in origin, transplantation of tissue from a different species results in
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TABLE 3
Effect of Reinfusion of Phototreated Autologous Lymphocytes
on Cardiac Xenograft Survival
Tx' n Survival MLC Antibody AMLR
Photo Cyclo 6 38 ± 18 Specific Suppression 5/6 dec 3/6
and Steroids vs. donor
Cyclo and 5 26 ± 16 Non-specific 5/6 inc 1/6
Steroids Suppression
aAbbreviations are as follows: Tx, treatment; n, number of animals; MLC, mixed
leukocyte culture; AMLR, autologous mixed lymphocyte reaction; Photo, photoche-
motherapy; dec, decreased formation of cytotoxic antibody; Cyclo, cyclosporine A;
inc, increased formation ofcytotoxic antibody.
rapid rejection due to the formation of anti-donor antibodies [14]. The addition of
photochemotherapy to conventional immunosuppressives was explored in a primate
model ofcardiac xenograft transplantation [14,1 5].
Baboons were heterotopically transplanted with cardiac grafts from cynomolgus
monkeys. The animals were started on cyclosporine A and steroids two days prior to
transplantation, and photopheresis was begun three days post-transplant and adminis-
tered twice a week thereafter. Control baboons did not receive photopheresis but were
treated with cyclosporine A and steroids. The animals were monitored for graft
survival, response to the donor in mixed lymphocyte culture, and the production of
anti-donor lymphocytotoxic antibodies.
The results demonstrated that photochemotherapy increased graft survival, specifi-
cally suppressed the mixed leukocyte culture response to the donor, resulted in an
increased response to self in some animals, and suppressed the formation ofanti-donor
antibodies (Table 3). In addition, biopsy-proven rejection episodes were reversed in two
photochemotherapy animals, whilecyclosporine-treated animals demonstrated pathol-
ogy consistent with progressive rejection. Control animals did develop inhibition ofthe
mixed leukocyte culture response to the donor, but this suppression was nonspecific,
affecting the response to unrelated allo- and xenoantigens, as well as the response to
the donor. No induction ofan autologous response to selfwas noted in controls, except
in one animal who had a pre-existent increased response in autologous mixed leukocyte
culture. Cytotoxic anti-donor antibody formation was not inhibited in control animals,
and levels ofantibody exceding 30 percent cytotoxicity led to rapid graft loss.
These studies demonstrate that the vigorous immune response to xenoantigens can
be suppressed by photopheresis given in a synergistic combination with cyclosporine A
and steroids. Photopheresis renders the nonspecific suppression, induced by cyclospo-
rine, specific for the cells responding to the donor xenoantigens. This procedure
permits unrelated immune responses to be preserved intact. The prolongation of graft
retention in phototreated animals probably relates to the inhibition of anti-donor
antibody formation induced by photochemotherapy. This finding may reflect the
capacity of photochemotherapy to develop a regulatory response in the host, which
suppresses the activated effector T cells that promote B-cell antibody production. The
duration of suppression mediated by photochemotherapy must be fairly long-lived,
since the graft is continually in place and constantly provokes an anti-donor response,
while phototherapy is only given twice weekly. Eventually, some T cells escape immune
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surveillance, and cumulative cellular and humoral damage results in graft destruction.
Perhaps the addition of other forms of immunosuppression such as monoclonal
antibody therapy to photopheresis and cyclosporine will result in even greater prolon-
gation oftrans-species engraftment.
The animal model systems have clarified some features of the mechanism by which
photopheresis induces a host response, although many questions remain to be
answered. The major conclusions that can be drawn from the current model systems
are:
1. Phototherapy targets T-cell-directed processes.
This conclusion was suggested by the results achieved during the therapy of
the inducer T-cell malignancy cutaneous T-cell lymphoma and was confirmed
in the murine lupus model where many of the features of the autoimmune
process are directly related to an unregulated proliferation ofbenign inducer T
lymphocytes. Treatment with psoralen and UVA inactivated effector cells of
autoimmune disease resulted in prophylactic and therapeutic amelioration of
the T-cell-related disease features. Moreover, in the transplantation model,
T-cell-directed cellular rejection and anti-donor antibody formation were
suppressed when photochemotherapy was added to conventional immunosup-
pressive regimens.
2. The suppression induced by photochemotherapy is specific for the immunoac-
tive cell type.
In the clinical trial of photopheresis, generalized immunocompetence was
preserved as demonstrated by the absence of infectious complications and the
retention of skin test responses. This observation was confirmed in the
xenograft transplantation model, where animals with a xenograft in place were
suppressed to the donor xenoantigen while maintaining thecapacity to respond
to other unrelated allo- and xenoantigens. This selective suppression was
achieved even though the animals were receiving cyclosporine A, which
rendered control animals nonspecifically suppressed to all histocompatibility
challenges.
3. Reinfusion ofthe phototreated cells results in recirculation ofthe photoinacti-
vated cells and their sequestration in sites where immune responses may be
engendered.
CTCL patients demonstrated large populations of antigen-negative cells
recirculating 24 to 48 hours post-reinfusion of the treated pheresis. This
finding suggested either that phototreated cells that lacked expression of cell
surface membrane antigens were recirculating or that large populations ofnull
cells had been released into the peripheral blood. In the radiolabeling studies,
the results demonstrate that phototreated cells do recirculate for a prolonged
period of time and are sequestered in organ systems. Phototreated antigen-
activated lymphocytes demonstrate altered recirculation patterns with
increased numbers of cells localized in the spleen and bone marrow of the
recipient. Both the spleen and the bone marrow could serve as sites for
induction of autoregulatory cell populations, which could suppress the immu-
noactive cell population.
4. An intact immune system is required for induction of a host response to
reinfused phototreated cells.
If photopheresis induces a host response to the reinfused photoinactivated
lymphocytes, an immunocompetent recipient is required. In the autoimmune
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mouse model, more efficacious results were achieved with prolonged survival
and pronounced inhibition of lymphoid organomegaly when younger mice
without active disease were treated prophylactically. Although some features
of the autoimmune process could be treated in actively diseased mice,
established kidney disease could not be remedied, and survival was not
improved. These results support the argument that the capacity to mount an
immunoregulatory response depends on the presence of a relatively intact
immune system.
5. Intact cells or membranes and psoralen plus UVA are required for induction of
an effective host response.
The results in the lupus model demonstrate that reinfusion ofuntreated cells
results in a partial response to therapy. Improved survival and extensive
suppression of lymphoproliferation are present only when phototreated auto-
immune splenocytes are infused. Lysed phototreated cells are not effective in
this protocol. Therefore, this form of therapy appears to require reinfusion of
whole cells or intact cell membranes treated by photoinactivation to achieve a
maximum response.
6. Conditions that are related to T-cell dysfunction should respond to photoche-
motherapy.
This contention is borne out by the results achieved in the MRL/I mouse
model where T-cell-related autoimmune disease is ameliorated by reinfusion
of phototreated effector cells and in the transplantation model where reinfu-
sion of autologous phototreated lymphocytes suppresses xenograft rejection.
These results suggest that beneficial clinical responses may be achieved by
photochemotherapy in some autoimmune diseases and as an adjunct immuno-
suppressive agent in transplantation.
Further studies are required in both animal models and clinical trials to answer
many remaining questions. The direct effect of photopheresis on B-cell-mediated
diseases is being studied in patients with B-cell chronic lymphocytic leukemia and in
discordant xenograft protocols where preformed antibodies to xenoantigens preclude
graft survival. Other mechanisms not considered in these protocols may play a
significant role in phototherapeutic regimens. Macrophages are relatively spared by
this treatment and their role in induction ofa host response may be significant. Release
of lymphokines by dying phototreated cells may also function to promote autoregula-
tory responses. Natural killer cells and cytotoxic T cells may promote the host response
that down-regulates the immunoactive cell type. The results of current protocols and
future studies will not only extend the clinical arsenal by adding a new immunosup-
pressive modality but will also further our understanding of immunoregulatory
responses.
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